Literature DB >> 15271171

Short course intravenous benzylpenicillin treatment of adults with meningococcal disease.

S Briggs1, R Ellis-Pegler, S Roberts, M Thomas, A Woodhouse.   

Abstract

BACKGROUND: Short-course treatment of meningococcal disease (including meningitis) with 4-5 days of an i.v. beta-lactam is of proven efficacy. Since April 1998, all adult patients with meningococcal disease admitted to Auckland Hospital were prospectively treated with 3 days of i.v. benzylpenicillin. AIMS: To assess the clinical features, laboratory findings, disease complications and outcome of patients with meningococcal disease prospectively treated with 3 days of i.v. benzylpenicillin.
METHODS: A retrospective chart review of all adult patients with meningococcal disease admitted to Auckland Hospital from April 1998 to December 2002 was conducted.
RESULTS: Ninety patients with definite (n = 72) or -probable (n = 16) meningococcal disease were admitted during the study period. Two were excluded on the basis of treatment duration. The remaining 88 patients received a mean +/- standard deviation duration of treatment of 3.1 +/- 0.5 days (excluding those who died while receiving treatment). Six patients (7%) died, four of whom while on treatment. There were no relapses.
CONCLUSION: Three days of i.v. benzylpenicillin for the treatment of adults with meningococcal disease is effective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271171     DOI: 10.1111/j.1445-5994.2004.00601.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  4 in total

Review 1.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

2.  Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.

Authors:  Achim J Kaasch; Gerd Fätkenheuer; Reinhild Prinz-Langenohl; Ursula Paulus; Martin Hellmich; Verena Weiß; Norma Jung; Siegbert Rieg; Winfried V Kern; Harald Seifert
Journal:  Trials       Date:  2015-10-09       Impact factor: 2.279

3.  Optimising Antibiotic Usage to Treat Bacterial Infections.

Authors:  Iona K Paterson; Andy Hoyle; Gabriela Ochoa; Craig Baker-Austin; Nick G H Taylor
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

Review 4.  Infection in the critically ill--questions we should be asking.

Authors:  John R Prowle; Sarah Heenen; Mervyn Singer
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.